Answer: The press release excerpt you provided does not disclose TherapeuticsMD’s cash‑and‑cash equivalents balance for the quarter ended June 30 2025. The summary only highlights net income (a modest $545 k profit versus a $1.05 M loss in Q2 2024) and per‑share earnings, but it omits the balance‑sheet line‑item for cash and cash equivalents.
What to do next:
- Locate the full filing: The company’s Form 10‑Q for Q2 2025 (or the complete press release) will contain the consolidated balance sheet, where cash and cash equivalents are reported.
- Check the 10‑K: The most recent annual report (2024 10‑K) can also give a baseline for cash levels and any disclosed changes in the “Liquidity and Capital Resources” section.
- Trading implication: Without the cash balance, it’s difficult to gauge the firm’s short‑term liquidity cushion or its capacity to fund future royalty acquisitions or dividend payouts. Confirming the cash position will help assess whether the modest swing to profitability is supported by a solid cash reserve (which could underpin a more bullish stance) or if the company is still operating on thin cash (suggesting a more cautious approach).
In short, the cash‑and‑cash equivalents figure is not included in the provided news snippet; you’ll need to review the full SEC filing or the complete earnings release to obtain that data before forming a definitive liquidity‑based trading view.